Research programme: enterotoxigenic Escherichia coli vaccine - Sanofi Pasteur/US Naval Medical Research Center

Drug Profile

Research programme: enterotoxigenic Escherichia coli vaccine - Sanofi Pasteur/US Naval Medical Research Center

Alternative Names: Travelers diarrhea vaccine - Sanofi Pasteur/NMRC; Travellers diarrhoea vaccine - Sanofi Pasteur/US NMRC

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Naval Medical Research Center; sanofi pasteur
  • Developer Naval Medical Research Center; Sanofi Pasteur
  • Class Bacterial vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Traveller's diarrhoea

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Traveller's-diarrhoea in USA
  • 12 Apr 2010 Sanofi Pasteur establishes CRADA with the US Naval Medical Research Center for the development of an enterotoxigenic Escherichia coli vaccine
  • 12 Apr 2010 Preclinical trials in Traveller's diarrhoea in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top